Benefits
H. pylori eradication — 56% vs 4% placebo
A randomized double-blinded placebo-controlled study reported that deglycyrrhizinated licorice (DGL) eliminated H. pylori infection in 56% of participants vs 4% for placebo. H. pylori is the primary cause of peptic ulcers and a significant stomach cancer risk factor. The 56% eradication rate compares favorably to first-line antibiotic regimens with fewer side effects.
Peptic and duodenal ulcer support
Small clinical trials have demonstrated DGL is as effective as H2 blockers (Pepcid, Tagamet class) for duodenal ulcer resolution, with fewer episodes of relapse vs the pharmaceutical alternative. Licorice's traditional use for epigastric pain and dyspepsia dates to ancient Egyptian times and Chinese medicine.
GERD symptom relief (phase III trial)
A standardized DGL extract has been evaluated in adults with gastroesophageal reflux symptoms. DGL is recognized as a natural and well-tolerated approach for relieving GERD symptoms via anti-inflammatory, antioxidant, and mucosal protective effects.
Mucosal anti-inflammatory and protective
DGL's bioactive flavonoids exert anti-inflammatory, antioxidant, and protective action on the gastrointestinal mucosa. The mechanism supports both acute symptom relief and long-term tissue healing. Mucosal protection is particularly relevant for those with NSAID-induced gastric damage or chronic stomach acid exposure.
Glabridin skin whitening and dermatology
Glabridin (a licorice isoflavonoid in BGG's portfolio) has documented tyrosinase inhibition activity — supporting skin whitening and hyperpigmentation reduction applications. Used extensively in personal care formulations particularly in Asian beauty markets. Different mechanism class than synthetic skin-lightening agents.
Licochalcone A anti-inflammatory dermatology
Licochalcone A is another licorice flavonoid with documented anti-inflammatory and antimicrobial effects on skin. Used in personal care for acne-prone skin, redness, and inflammatory skin conditions. The flavonoid bioactives in BGG's Glycyrrhizina portfolio extend applications beyond gut health to dermatology and personal care.
Reduced side effect profile via deglycyrrhizination
Deglycyrrhizinated licorice (DGL) does not have the adrenocorticoid effect of native glycyrrhiza (sodium retention leading to hypertension) and is less hepatotoxic than the native plant. The deglycyrrhizination process — patented in 1962 — removes the problematic glycyrrhizin while preserving the therapeutic flavonoid content. Supports safer long-term use.
GABAergic and antioxidant neuroprotection
Licorice flavonoids may contribute to GABAergic neurotransmission modulation with mouse model evidence of protective effects in epilepsy. Liquiritigenin can protect against glutamate-mediated neurotoxicity in mouse hippocampal neurons by reducing ROS production. The neuroprotective effects extend licorice's applications beyond GI.
Mechanism of action
Mucosal protection via flavonoid anti-inflammatory
Licorice flavonoids exert anti-inflammatory effects on GI mucosa — reducing inflammatory mediators (NF-κB, COX-2, leukotrienes) that drive ulcer formation and GERD symptoms. The anti-inflammatory mechanism complements direct mucosa-protective effects on epithelial cell renewal.
H. pylori antimicrobial flavonoids
Licorice-derived flavonoids have documented direct antimicrobial effects on Helicobacter pylori — the bacterium causing the majority of peptic ulcers and a major stomach cancer risk factor. The 56% eradication rate vs 4% placebo in clinical trials supports clinically meaningful antimicrobial activity.
Tyrosinase inhibition (skin whitening)
Glabridin inhibits tyrosinase — the rate-limiting enzyme in melanin synthesis. Mechanism supports skin-whitening and hyperpigmentation reduction applications. The licorice flavonoids work via the same target as topical hydroquinone but with a more favorable safety profile.
11β-HSD2 inhibition (native glycyrrhizin)
Native glycyrrhizin (not present in DGL) inhibits 11β-hydroxysteroid dehydrogenase type 2 — the enzyme that inactivates cortisol. Inhibition leads to mineralocorticoid-like effects (sodium retention, hypertension, hypokalemia) at high doses. Deglycyrrhizination removes this mechanism while preserving therapeutic flavonoid effects.
GABAergic modulation and neuroprotection
Licorice flavonoid-rich extracts of G. glabra modulate GABAergic inhibitory neurotransmission. Liquiritigenin protects against glutamate-mediated excitotoxicity in mouse hippocampal neurons via reduced ROS production and pro-apoptotic factor reduction. Mechanism may underlie reports of licorice neuroprotective applications.
Clinical trials
Robust randomized double-blinded placebo-controlled clinical trial evaluating deglycyrrhizinated licorice (DGL) for Helicobacter pylori eradication. 2-month intervention. Foundational evidence for licorice's antimicrobial applications in GI infection.
Adults with confirmed H. pylori infection. 2-month DGL vs placebo intervention.
DGL eliminated H. pylori infection in 56% of participants vs 4% for placebo — a 14× higher eradication rate. Effects attributable to bioactive flavonoids in licorice. The clinically meaningful eradication rate supports DGL applications for H. pylori-driven ulcer disease. Comparable to or better than some pharmaceutical alternatives with fewer side effects.
Phase III placebo-controlled double-blind randomized clinical study evaluating standardized DGL extract twice daily for 28 days in adults with gastroesophageal reflux. Capsule format. Foundational evidence for DGL in GERD applications.
200 adults aged 18-60 with symptoms compatible with gastroesophageal reflux for at least one month.
DGL extract demonstrated efficacy and safety vs placebo for GERD symptom relief through anti-inflammatory, antioxidant, and GI mucosa protective action. Phase III scale (200 adults) is appropriate for regulatory consideration. Supports DGL as a natural and well-tolerated approach for GERD symptom relief.
Class evidence from clinical trials of licorice flavonoid oil (Glavonoid®) for metabolic effects. 16-week supplementation studies in people with knee osteoarthritis and metabolism trials with light exercise. Provides class evidence for licorice flavonoid metabolic applications.
Various — n=50 knee osteoarthritis study, n=11-17 metabolic studies.
Glabridin-rich licorice flavonoid oil increased trunk muscle mass in knee osteoarthritis subjects (+0.17±1.1 vs placebo -0.57±1.0 kg) after 16 weeks. Mechanism: AMPK-mediated GLUT4 translocation increasing muscle glucose transport. Higher fat oxidation during light exercise (30-40% VO2max) — dose-dependent. Class evidence for metabolic and muscle applications.